Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models.
Gene therapy rescued a fatal liver disorder in mice, setting the stage for human trials of this potential cure for a rare childhood disease.
In vivo liver-targeted lentiviral gene therapy safely and effectively rescued key features of ARC syndrome (a rare, early-lethal disorder of bile flow and liver disease) in a mouse model, with improved survival, growth, and liver function. Published in Nature Communications, this preclinical study from Great Ormond Street/UCL supports advancing toward clinical gene therapy for ARC.
What the study was
- Study design
- Preclinical in vivo gene therapy study in mouse model
- Population
- Mouse model of ARC syndrome (VPS33B deficiency)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nature Communications
Why it surfaced
High-impact journal (Nat Commun), rare disease (ARC syndrome), gene therapy proof-of-concept. Score capped at 5 per non-human species rule.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.